View ValuationOctopus Biosafety 将来の成長Future 基準チェック /06現在、 Octopus Biosafetyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Machinery 収益成長29.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jun 03New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$447k). Minor Risk Market cap is less than US$100m (€28.0m market cap, or US$32.4m).New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 41% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.1m).New Risk • Dec 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$451k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.0m).New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risk Market cap is less than US$100m (€31.8m market cap, or US$37.3m).New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.55m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).お知らせ • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray Franceお知らせ • Aug 09Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024. Location: cyanophy labooratoires, 140 av du 12 juillet 1998, aix en provence FranceNew Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$300k). Market cap is less than US$10m (€1.09m market cap, or US$1.18m).New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$306k). Market cap is less than US$10m (€811.0k market cap, or US$893.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€636k). Revenue has declined by 19% over the past year. Revenue is less than US$1m (€537k revenue, or US$578k). Market cap is less than US$10m (€1.35m market cap, or US$1.45m).Is New 90 Day High Low • Dec 21New 90-day low: €1.45The company is down 52% from its price of €3.04 on 22 September 2020. The French market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 8.0% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: €2.70The company is down 23% from its price of €3.52 on 02 September 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 1.0% over the same period.Is New 90 Day High Low • Oct 06New 90-day low: €2.80The company is down 26% from its price of €3.80 on 08 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is flat over the same period.Is New 90 Day High Low • Sep 18New 90-day low: €3.30The company is down 17% from its price of €4.00 on 19 June 2020. The French market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 7.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Octopus Biosafety は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ENXTPA:MLOCT - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20240-1N/AN/AN/A12/31/20231-2N/AN/AN/A12/31/20220-1N/AN/AN/A12/31/20211-1N/AN/AN/A12/31/20201-1N/AN/AN/A12/31/20190-1N/AN/AN/A7/31/201710N/AN/AN/A6/30/201600N/AN/AN/A6/30/201500N/AN/AN/Aアナリストによる今後の成長予測収入対貯蓄率: MLOCTの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MLOCTの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MLOCTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MLOCTの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MLOCTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MLOCTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/25 20:45終値2026/06/25 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Octopus Biosafety SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 03New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$447k). Minor Risk Market cap is less than US$100m (€28.0m market cap, or US$32.4m).
New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 41% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.1m).
New Risk • Dec 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$451k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.0m).
New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risk Market cap is less than US$100m (€31.8m market cap, or US$37.3m).
New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.55m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).
お知らせ • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray France
お知らせ • Aug 09Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024. Location: cyanophy labooratoires, 140 av du 12 juillet 1998, aix en provence France
New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$300k). Market cap is less than US$10m (€1.09m market cap, or US$1.18m).
New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$306k). Market cap is less than US$10m (€811.0k market cap, or US$893.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€636k). Revenue has declined by 19% over the past year. Revenue is less than US$1m (€537k revenue, or US$578k). Market cap is less than US$10m (€1.35m market cap, or US$1.45m).
Is New 90 Day High Low • Dec 21New 90-day low: €1.45The company is down 52% from its price of €3.04 on 22 September 2020. The French market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: €2.70The company is down 23% from its price of €3.52 on 02 September 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Oct 06New 90-day low: €2.80The company is down 26% from its price of €3.80 on 08 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is flat over the same period.
Is New 90 Day High Low • Sep 18New 90-day low: €3.30The company is down 17% from its price of €4.00 on 19 June 2020. The French market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 7.0% over the same period.